Jump to Navigation

User login

Facebook Connect

NLA Meetings

Meeting Info

NLA Clinical Lipid Update – Spring 2014

Maui, Hawaii

Thursday, March 13 • 3:00–6:00 pm
Friday, March 14 • 8:00 am–2:15 pm
Saturday, March 15 • 8:00 am–2:45 pm
Sunday, March 16 • 8:00 am- 2:45 pm
$575 NLA Members, $995 Non-members, $200 Trainees

Registration: $575

Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, Advanced Practice Registered Nurses, and registered dietitians with an interest in lipid management.

This program is supported in part by the American Heart Association’s Councils on Clinical Cardiology, Epidemiology and Prevention, and Nutrition, Physical Activity and Metabolism.”

Pre-Conference Courses:
Venue:
Waldorf Astoria Grand Wailea Hotel

Hotel Information:

Waldorf Astoria Grand Wailea Hotel
3850 Wailea Alanui Dr, Wailea-Makena, HI 96753

For reservations, please call 1-800-888-6100 and ask for the National Lipid Association room rate. A special room rate starting at $235 per night plus tax has been arranged. The rate is available until February 11, 2014, or until the room block is filled.  Please make your reservation early as we do anticipate that the room block will sell out.

A free service was designed to help you find someone to share rooming expenses with for the NLA Spring CLU in Maui Hawaii. Click here to submit your request for a roommate. We’ll send you eligible results as soon as they arrive. Note that we will share the information you provide with other individuals whenever they meet your specified criteria.

About the Hotel
Immerse yourself in idyllic Hawaiian luxury at the Grand Wailea, Maui. Discover lush Polynesian landscapes and perfect ocean sunsets from this Maui resort offering indulgent relaxation and tropical adventure. The hotel is ideally located on beautiful Maui, voted the “Best Island in the World” by the readers of Condé Nast Traveler. To learn more about the hotel and Grand Wailea, Maui, please visit http://www.grandwailea.com.

Take advantage of these wonderful hotel features:

  • 780 spacious guestrooms, including 52 suites
  • Wailea Canyon Activity Pool with nine pools and multiple lazy rivers
  • Spa Grande, renowned as the best spa in Maui
  • Award-winning fine dining
  • A variety of shops for that perfect Maui memento
  • A 2,500-square-foot state-of-the art fitness center
  • Five championship golf courses nearby
  • Eleven tennis courts at the famed Wailea tennis club
  • Camp Grande offers exclusive activities for ages 5-12

 

Thursday, March 13, 2014

Session I: Diagnosis and Lipid Management in the Metabolic Syndrome: Developments from Around the World

3:00 - 3:10 PM Presidents Welcome and Introductions B Bottenberg, DO, FNLA & Elizabeth J. Jackson, MSN, CNS, CLS, FNLA
3:10 - 3:40 PM Keynote: Guidelines for Lipid Management in 2014

William Virgil Brown, MD, FNLA

3:40 - 4:10 PM Lipoprotein Transport in the Metabolic Syndrome: Integrative Lessons from Tracer Studies

Gerald F. Watts, DSc, PhD, MD

4:10 - 4:40 PM The Concept of Metabolic Syndrome and Lipid Management

Yuji Matsuzawa, MD, PhD

5:10 - 5:40 PM Characteristics of the Metabolic Syndrome in Europe: Diagnosis and Lipid Management

Cesare R. Sirtori, MD, PhD

5:40 - 6:00 PM Q & A Panel
6:30 - 9:00 PM Foundation of the National Lipid Association Special Event: Luau

Friday, March 14, 2014

Session II- Strategies of Treatment in Primary Prevention

7:00 - 7:45 AM Breakfast in Exhibit Hall
8:00 - 8:30 AM Recent Advances in the Care of FH

Gerald F. Watts, DSc, PhD, MD

8:30 - 9:00 AM Nipping Coronary Heart Disease in the Bud

Daniel Steinberg, MD, PhD

9:00 - 9:30 AM Discrepancies and Barriers Related to Screening and Treating Hypercholesterolemia for Primary Prevention

Catherine J. McNeal, MD, PhD, FNLA

9:30 - 9:45 AM Q & A Panel

Session III- Ask the Experts an HDL Review

10:00 - 10:25 AM HDL: State of the Lipoprotein

Benjamin J. Ansell, MD, FNLA

10:25 - 11:15 AM Consult the Experts Panel

William Virgil Brown, MD, FNLA; Ronald Krauss, MD; Terry Jacobson, MD, FNLA

11:30 - 12:30 Lunch in Exhibit Hall

Session IV- New Targets for Atherogenesis

12:30 - 1:00 PM Mitochondria in Aging, Diabetes, and Atherosclerosis – Introducing Humanin

Pinchas Cohen, MD

1:00 - 1:30 PM The Hepatic Sortilin Pathway- A New Target for Reducing LDL and CVD Risk

Ronald M. Krauss, MD

1:30 - 2:00 PM LXR Signaling Pathways in Lipid Metabolism

Peter Tontonoz, MD, PhD

2:00 - 2:15 PM Q & A Panel

Saturday, March 15, 2014

Session V- Cardiovascular Risk in Asians and Pacific Islanders

7:00 - 7:45 AM Breakfast in Exhibit Hall
8:00 - 8:25 AM Lessons and Implications on Preventive Cardiology from the Honolulu Heart Program and Migration Studies

Beatriz Rodriguez, MD, PhD

8:25 - 8:50 AM Addressing Cardiometabolic Health Disparities in Native Hawaiians and Pacific Islanders

Joseph Keawe’aimoku Kaholokula, PhD

8:50 - 9:15 AM Evidence from Cardiovascular Risk Reduction Efforts in Asian Populations

Nathan D. Wong, PhD

9:15 - 9:40 AM Addressing CVD Risk in Asian Americans: The AHA Scientific Advisory on CVD in Asian Americans

Latha Palaniappan, MD, MS

9:40 - 10:00 AM Q & A Panel

Session VI- Debate: How Close are we to Personalizing CVD Prevention with Genetics?

10:15 - 10:40 AM Personalized CVD Risk: Yes- Genetic Individualization

John D. Brunzell, MD

10:40 - 11:05 AM Genetic Individualization for Lipid Therapy: We are Not There Yet

Sekar Kathiresan, MD

11:05 - 11:15 AM Rebuttal
11:15 - 11:45 AM Q & A Panel
11:45 - 12:45 Lunch in Exhibit Hall

Workshop 1: Lipids on the Front Lines

12:45 - 1:15 PM Interpretation of Results: How Deep Should We Look?

Elizabeth J. Jackson, MSN, CNS, CLS, FNLA

1:15 - 1:45 PM Navigating Around the Roadblocks: Lipid Management, Barriers and Byways

Randy W. Burden, PharmD, MDiv

1:45 - 2:15 PM Cardiometabolic Benefits of Low-Intensity Physical Activity

Marc T. Hamilton, PhD

2:15 - 2:45 PM Case Study Wrap Up and Q&A

Workshop 2: Lipid Science and Research

12:45 - 1:15 PM Improving Clinical Trial Design: Why and How?

Eliot A. Brinton, MD, FNLA

1:15 - 1:45 PM Cardiovascular Epidemiologic Studies: Framingham and Beyond

Sekar Kathiresan, MD

1:45 - 2:15 PM Framingham and Beyond: Lessons Learned and Future Needs from Key Epidemiologic Studies

Nathan D. Wong, PhD

2:15 - 2:45 PM Case Study Wrap Up and Q&A

Sunday, March 16, 2014

Session VII- Debate: Is it Time to Stop using Fibrates Combined with Statins?

7:00 - 7:45 AM Breakfast
8:00 - 8:25 AM Is it Time to Stop Using Fibrates in the Era of Statin Therapy?

Jocelyne R. Benatar, MBChB

8:25 - 8:50 AM Can Fibrates Improve CVD Reduction with Statins? Yes!

Eliot A. Brinton, MD, FNLA

8:50 - 9:10 AM Rebuttal
9:10 - 9:40 AM Q&A Panel

Session VIII- Atherosclerosis Imaging Through the Ages

9:55 - 10:20 AM What do Mummies tell us about Atherosclerosis?

Greg Thomas, MD, MPH

10:20 - 10:45 AM Modern Day Technologies to Assess Atherosclerotic Burden

Edward Chafizadeh, MD

10:45 - 11:10 AM Human and Animal Atherosclerotic Effects of Apheresis, MTP inhibition and ApoB Antisense Therapy

James Falko, MD

11:10 - 11:30 AM Q&A Panel
11:30 - 12:30 Lunch

Session IX- CVD Reduction Through Fish Oils, Diet and Supplements

12:30 - 1:00 PM Fish Oil and Fatty Liver

Kathleen Wyne, MD, PhD, FNLA

1:00 - 1:30 PM Omega 3's & CVD: High vs. Low Dose

Terry A. Jacobson, MD, FNLA

1:30 - 2:00 PM Dietary Supplements and CVD- What to Use and What to Avoid

Forrest Batz, PharmD

2:00 - 2:30 PM Mediterranean, DASH & TLC Dietary Patterns: Mechanisms for CVD Reduction

Geeta Sikand, RD, MA

2:30 - 2:45 PM Q&A Panel

Upon completion of the educational activity, participants should be able to:

Educational Objectives
At the conclusion of this activity, Registered Nurses and Nurse Practitioners should be able to provide appropriate care and counsel for patients and their families.

Session I: Lipid Management in Various Populations

  • Recognize population differences that may impact clinical
  • Implement novel interventions to reduce cardiovascular risk in special population
  • Manage dyslipidemia in special populations based on gender, culture, and disease variables
  • Compare guidelines on the diagnosis, management and treatment of dyslipidemia in various populations
  • Utilize current treatment strategies for patients with metabolic syndrome

Session II: Strategies of Treatment in Primary Prevention 

  • Preform universal screening during childhood and cascade lipid screening of family members of known FH patients
  • Implement appropriate diagnosis strategies in pediatric patients
  • Identify potential barriers to the treatment of lipid disorders
  • Utilize current guidelines on the diagnosis, management and treatment of pediatric patients with dyslipidemia

Session III: Ask the Experts: An HDL Review

  • Discuss recent evidence regarding the utility of HDL as a target for CVD risk modification including the clinical implications for patient management
  • Compare the relative effectiveness of existing treatments to raise HDL and reduce CVD risk
  • Describe the role of HDL as a risk factor versus a target for treatment

Session IV: New Targets for Atherogenesis

  • Assess traditional and emerging markers for atherosclerotic cardiovascular disease
  • Explain the various pathways of atherogenesis, especially the role of apolipoproteins as carriers of cholesterol, and the role of inflammation
  • Evaluate the changing landscape of dyslipidemia management, including the identification of secondary therapeutic targets

Session V: Cardiovascular Risk in Asians and Pacific Islanders

  • Recognize population differences that may impact clinical care
  • Implement novel interventions to reduce cardiovascular risk in special populations
  • Evaluate biological and sociocultural determinants in healthcare disparities and disease in special populations
  • Utilize guidelines for prevention and treatment strategies in special populations

Session VI: Debate: How Close are We to Personalizing CVD Prevention with Genetics?

  • Apply insight from human genetics to identify novel therapeutic targets that may prevent atherosclerotic cardiovascular disease
  • Review management options and emerging therapies for dyslipidemia and related cardiometabolic conditions for the primary and secondary prevention of CVD
  • Evaluate the use of genetics to modify lipid therapies

Special Session: Lipids on the Front Lines

  • Evaluate clinical scenarios where advanced lipid testing may be used to identify risk
  • Optimize management strategies for patients with complex lipid abnormalities
  • Critique the role of drug therapies, nutrition, and therapeutic lifestyle changes in the management of CVD risk

Special Session: Lipid Science and Research

  • Discuss clinical trials and their role in cardiovascular prevention
  • Critically appraise the design of clinical trials and their impacts on study outcomes
  • Discuss epidemiologic and statistical evidence related to cardiovascular disease risk

Session VII: Debate: Is it Time to Stop Using Fibrates Combined with Statins?

  • Describe combination therapies for the management of complex lipid disorders and residual risk.
  • Evaluate the safety and efficacy data for statins  and fibrates in reaching therapeutic targets

Session VIII: Atherosclerosis Imaging Through the Ages

  • Discuss the roles of imaging in cardiovascular disease risk evaluation
  • Review the atherosclerotic effects of various treatment strategies for cardiovascular disease.

Session IX: CVD Reduction Through Fish Oils, Diet and Supplements

  • Utilize effective diet and lifestyle strategies for dyslipidemia management
  • Interpret evidence from recent clinical trials of approved omega-3 fatty acids and those in clinical development
  • Compare alternate therapies and treatments of dyslipidemia in various populations
  • Identify guidelines for nutrient intake and food choices to meet those guidelines

 

CME Credit for this activity is being provided by the National Lipid Association

Physicians

The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The National Lipid Association designates this live activity for a maximum of 18.75 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Dietitians

The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 19 continuing professional education units (CPEUs) for completion of this program/ materials.

American Academy of Family Physicians

This Live activity, 2014 Maui Clinical Lipid Update- Atheroprevention: Global Perspectives & Evolving Concepts, with a beginning date of 03/13/2014, has been reviewed and is acceptable for up to 18.75 Elective credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

CE credit provided by Postgraduate Institute for Medicine.

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Session I: Universal Activity Number 0809-9999-14-002-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 3.0 contact hour(s) (.30 CEUs) of the Accreditation Council for Pharmacy Education

Session II: Universal Activity Number 0809-9999-14-003-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (.175 CEUs) of the Accreditation Council for Pharmacy Education

Session III: Universal Activity Number 0809-9999-14-004-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125 CEUs) of the Accreditation Council for Pharmacy Education

Session IV: Universal Activity Number 0809-9999-14-005-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (.175 CEUs) of the Accreditation Council for Pharmacy Education

Session V: Universal Activity Number 0809-9999-14-006-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Session VI: Universal Activity Number 0809-9999-14-007-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (.15 CEUs) of the Accreditation Council for Pharmacy Education

Special Session: Lipidology on the Front Lines-Universal Activity Number 0809-9999-14-011-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Special Session: Lipid Science and Research- Universal Activity Number 0809-9999-14-012-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Session VII: Universal Activity Number 0809-9999-14-008-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (.175 CEUs) of the Accreditation Council for Pharmacy Education

Session VIII: Universal Activity Number 0809-9999-14-009-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (.15 CEUs) of the Accreditation Council for Pharmacy Education

Session IX: Universal Activity Number 0809-9999-14-010-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 2.25 contact hour(s) (.225 CEUs) of the Accreditation Council for Pharmacy Education

Nursing

This educational activity for 20.2 contact hours is provided by the Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Session I- 2.8 credits; Session II- 1.7 credits; Session III- 1.2 credits; Session IV- 1.7 credits; Session V- 2 credits; Session VI- 1.5 credits; Special Session- Lipidology on the Front Lines- 2 credits; Special Session- Lipid Science and Research- 2 credits; Session VII- 1.6 credits; Session VIII- 1.5 credits; Session IX- 2.2 credits.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Criteria for Success:
Statements of credit will be awarded based on the participant´s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme.
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

Disclosure Statement:
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.

Commercial Support:
Full notification of commercial support will be provided in the activity syllabus

B Alan Bottenberg, DO, FACOI, FNLA

President, Pacific Lipid Association
Physician
Carson Tahoe Hospital
Northern Nevada Lipidology
Internal Medicine Associates
Carson City, NV
Diplomate, American Board of Clinical Lipidology

Elizabeth J. Jackson, MSN, CNS, CLS, FNLA

President, Southwest Lipid Association
Cardiovascular Clinical Nurse Specialist
Clinical Lipid Specialist
Cardio Texas
Austin, TX

Paul D. Rosenblit, MD, PhD, FACE, FNLA

President-Elect, Pacific Lipid Association
Director & Principal Investigator,
Diabetes/Lipid Management & Research Center
Huntington Beach, CA
Clinical Professor of Medicine
Division of Endocrinology
Diabetes, and Metabolism
University of California, Irvine, (UCI)
School of Medicine
Irvine, CA
Co-Director, Diabetes Out-Patient Clinic, UCI Irvine Medical Center
Orange, CA
Diplomate, American Board of Clinical Lipidology

Krishnaswami Vijayaraghavan, MD, MS, FNLA

President Elect, Southwest Lipid Association
Professor of Medicine, Midwestern UniversityGlendale, Arizona
Vice President, Scottsdale Cardiovascular Center
President, Cardiorenal Society of America
Scottsdale, AZ
Diplomate, American Board of Clinical Lipidology

Benjamin J. Ansell, MD, FACP, FACC, FNLA

Professr of Medicine
Division of Cardiology and General Internal Medicine
UCLA Sch0ol of Medicine
Los Angeles, CA
Diplomate, American Board of Clinical Lipidology

Forrest Batz, PharmD

Assistant Professor of Pharmacy Practices
The Daniel K Inouye College of Pharmacy
University of Hawaii at Hilo
Hilo, HI

Jocelyne R. Benatar, MBChB

Medical Officer
Cardiovascular Research Unit and Cardiology Department
Auckland City Hospital
Auckland, New Zealand

Eliot A. Brinton, MD, FNLA

Director, Metabolism Section of Cardiovascular Genetics
University of Utah College of Medicine
Salt Lake City, UT
Diplomate, American Board of Clinical Lipidology

William Virgil Brown, MD, FNLA

Charles Howard Candler Professor Emeritus
Emory University School of Medicine
Atlanta, GA
Diplomate, American Board of Clinical Lipidology

John D. Brunzell, MD, FAHA

Professor Emeritus of Medicine, Active
Department of Medicine
Division of Metabolism
University of Washington
Seattle, WA
Diplomate, American Board of Clinical Lipidology

Randy W. Burden, PharmD, MDiv, PhC, FNLA

Pharmacist Clinician
Presbyterian Medical Group
Belen, NM

Edward R. Chafizadeh, MD

President, Cardio Texas
Austin, TX

Pichas Cohen, MD

Dean and Executive Director
Professor of Gerontology and Medicine
USC Davis School of Gerontology
Las Angeles, CA

James M. Falko, MD, FACE, FACC, FNLA

Clinical Professor of Medicine
University of Colorado, Denver
Lone Tree, CO
Diplomate, American Board of Clinical Lipidology

Marc T. Hamilton, PhD

Professor
Director Inactivity Physiology Department
Pennington Biomedical Research Center
Baton Rouge, LA

Terry A. Jacobson, MD, FACP, FNLA

Professor of Medicine
Director, Office of Health Promotion and Disease Prevention
Emory University
Atlanta, GA
Diplomate, American Board of Clinical Lipidology

Joseph Keawe’aimoku Kaholokula, PhD

Associate Professor
Chair of Native Hawaiian Health
John A. Burns School of Medicine
Honolulu, HI

Sekar Kathiresan, MD

Associate Professor of Medicine
Harvard Medical School
Director,
Preventive Cardiology
Massachusetts General Hospital
Boston, MA

Ronald M. Krauss, MD

Senior Scientist and Director
Atherosclerosis Research, Children's Hospital Oakland Research Institute
Adjunct Professor,
Department of Medicine, UCSF
Adjunct Professor
Department of Nutritional Sciences
University of California, Berkeley
Guest Senior Scientist
Department of Genome Sciences
Lawrence Berkeley National Laboratory
Oakland, CA
Diplomate, American Board of Clinical Lipidology

Yuji Matsuzawa, MD, PhD

Director, Sumitomo Hospital
Emeritus Professor of Osaka University
Osaka, Japan

Catherine J. McNeal, MD, PhD, FNLA

Associate Professor of Internal Medicine
Associate Professor of Pediatrics
Scott & White Healthcare
Texas A&M University College of Medicine
Temple, TX
Diplomate, American Board of Clinical Lipidology

Latha Palaniappan, MD, MS

Medical Director
Clinical Research
Palo Alto Medical Foundation
Adjunct Clinical Associate Professor
Stanford University
Palo Alto, CA

Beatriz L. Rodriguez, MD, PhD, MPH

Professor
Department of Geriatric Medicine
John A. Burns School of Medicine
University of Hawaii at Manoa
Honolulu, HI

Shaukat M. Sadikot, MD

President-Elect, International Diabetes Federation
President, Diabetes India
Mumbai, India

Geeta Sikand, MA, RD, CLS, FNLA

Associate Clinical Professor of Medicine
Cardiology University of California Irvine
Irvine, CA

Cesare R. Sirtori, MD, PhD

Director, Center for Dyslipidemias
Niguarda Ca' Granda Hospital
Milan, Italy

Daniel Steinberg, MD, PhD

Emeritus Professor of Medicine
University of California San Diego
La Jolla, CA
Diplomate, American Board of Clinical Lipidology

Gregory S. Thomas, MD, MPH

Medical Director
Memorial Care Heart & Vascular Institute
Long Beach Memorial Medical Center
Clinical Professor
University of California, Irvine
Dana Point, CA

Peter Tontonoz, MD, PhD

Professor
University of California
Los Angeles, CA

Gerald F. Watts, DSc, PhD, MD, FRACP, FRCP

Winthrop Professor
Cardiometabolic Medicine
University of Western Australia
Perth, Western Australia

Nathan D. Wong, PhD, FACC, FAHA

Professor and Director
Heart Disease Prevention Program
Division of Cardiology
University of California, Irvine
Immediate Past President, American Society for Preventive Cardiology
Irvine, CA

Kathleen Wyne, MD, PhD, FNLA

Director, Clinical Research
Diabetes Research Center
Houston Methodist Hospital
Houston, TX
Diplomate, American Board of Clinical Lipidology

We can pre-fill much of this information for you if you are a member and login first. If you are a member; but have not yet setup your web account, or cannot remember your username and password, try writing the webmaster first.

NLA Offers a substantial meeting registration discount to Members. If you would like to join the NLA at $100 annually, please click here.

 

*Registration and payment must be received no later than January 31, 2014. After this date a syllabus and name badge cannot be guaranteed.

Cancellation: Telephone cancellations will not be accepted. A written notice of cancellation must be received no later than January 31, 2014. This includes social events and guest fees. There will be a $25 fee for all cancellations.

*Must be logged in to see discounted NLA member rate. If you are not logged in, please use your credentials to log in at the top of the page.

Plan now for your company to participate in the National Lipid Association’s premier scientific meeting series in 2014. Our meetings provide you with a unique opportunity to reach our target audience of Lipidologists, Cardiologists, Endocrinologists, Primary Care Physicians and Allied Health Professionals involved in dyslipidemia management, as well as our distinguished board and faculty.

Our numerous sponsorship opportunities allow you to connect with our members in a whole new way, providing you with maximum return on your investment. The exhibit hall provides a unique setting for you and your company’s representatives to interact daily with attendees as they study the latest advances in their professions. Exhibiting in Hawaii is an excellent way to showcase your commitment to the NLA. You may take these opportunities to acquaint the attendees with the benefits of your products and services in an intimate setting.

If you are interested in becoming a grant supporter or have any questions regarding exhibit opportunities, please contact the Event Department directly, contact info below.

the Maui Exhibit Prospectus

 

 

You also can download The Annual Scientific Sessions Exhibit Prospectus (Orlando, FL) and The Fall Clinical Lipid Update Exhibit Prospectus (Indianapolis, IN).

 

 

Contact Info:
Theresa Henson
Event Coordinator
904-309-6207
thenson@lipid.org

 

Atherotech
Atherotech’s proprietary VAP® Lipid Panel enables clinicians to accurately stratify a patient’s risk and deliver personalized treatment to improve health outcomes. For more information, please visit www.atherotech.com.

Endurance Products Company
Endurance Products Company (EPC), is a manufacturer of dietary supplements featuring our proprietary wax-matrix, controlled-release technology.  Endur-acin® is our extended-release niacin, which has demonstrated excellent tolerability in clinical study. See published clinical references at www.enduranceresearch.com.

LipoScience Inc
LipoScience Inc, offers the NMR LipoProfile® test, the only FDA-cleared blood test that directly quantifies LDL particles. LDL-P by NMR is a more clinically reliable measure of LDL used to manage patients with increased CVD risk.

Synageva
Synageva BioPharma Corporation is a biopharmaceutical company working to deliver breakthrough medicines globally for patients suffering from rare, devastating diseases. Our lead program, sebelipase alfa (SBC-102), is a recombinant human enzyme replacement therapy for Lysosomal Acid Lipase Deficiency (LAL D), a lysosomal storage disorder (LSD).

DiaDexus
The PLAC® Test is a simple blood test that measures Lp-PLA2, a vascular-specific inflammatory marker critical in the formation of rupture-prone plaque. www.plactest.com
 

Traditional Hawaiian Luau

Thursday, March 13

$150 per person

Support the Foundation of the NLA at a Hawaiian Luau, a traditional party filled with Hawaiian foods, music and dance. Sunset is the perfect time for a traditional Hawaiian luau on the shores of Maui. Settle down under the stars while you listen to live music and watch skilled performances of the hula. Some luau showcase dances from across Polynesia as well, like the frenetic Tahitian dance and the thrilling Samoan fire-knife dance. The Maui Luau on a balmy evening under the stars will transport you to the days of early Polynesia as you enjoy traditional music, dance, food and fun.

Exhibit Hall, Product Theater Workshops and Non-CME Events

See the latest pharmaceuticals, equipment and other essential products and services to help you practice more effectively. Details on specific product theater workshops coming soon.

2014 SATELLITE SYMPOSIA GUIDELINES

The National Lipid Association (NLA) has established that independently developed and CME/CE certified satellite symposia held in conjunction with the scientific meetings of the NLA are valuable opportunities to provide continuing education for our members. In this regard, we are pleased to offer satellite symposia slots in conjunction with our 2014 NLA Meeting Series.
 
Satellite symposia are non-commercial CME- and CE-certified activities addressing educational needs and performance gaps that complement the NLA scientific program agenda. They may include one or a number of speakers and may cover one or several topics addressing the educational gaps of lipid specialists.
 
The following deadlines and guidelines provide important information about holding a
satellite symposium at an NLA meeting and the process for completing a symposium proposal. Please contact the NLA business development department directly (contact below) should there be any questions or further information required. See you in 2014!
 

DOWNLOAD SATELLITE SYMPOSIA GUIDELINES 2014

 

 

Contact:
Amina Resheidat
Program Coordinator
904-309-6212

aresheidat@lipid.org

0
No votes yet

Saturday, March 15
 
Workshop 1: Lipids on the Front Lines
12:45 - 1:15 PM Interpreting results: is There a Role for Advanced Lipid Testing? Elizabeth J. Jackson, MSN, CNS, CLS, FNLA
1:15 - 1:45 PM Navigating Around the Roadblocks: Lipid Management, Barriers and Byways Randy W. Burden, PharmD, MDiv, PhC, CLS, FNLA
1:45 - 2:15 PM Cardiometabolic Benefits of Low - Intensity Physical Activity Marc Hamilton, PhD
2:15 - 2:45 PM Case Study Wrap Up and Q&A  

 

Workshop 2: Lipid Science and Research
12:45 - 1:15 PM How do we Avoid Faltering in Design of Clinical Trials? Eliot Brinton, MD, FNLA*
1:15 - 1:45 PM Should we Change the Endpoints in Cardiovascular Research Outcomes? Sekar Kathiresan, MD
1:45 - 2:15 PM Framingham and Beyond: Lessons Learned and Future Needs from Key Epidemiologic Studies Nathan D. Wong, PhD
2:15 - 2:45 PM Case Study Wrap Up and Q&A  

 

Please select one workshop. Workshop included in your registration.

Monoclonal Antibodies (mAbs): Three Decades of Innovation and Progress

 
When:
May 2, 2014 at 12:00-1:00PM

 
Faculty:

Eli M. Roth MD, FACC, FNLA

Medical Director, Sterling Research Group

Professor of Clinical Medicine, University of Cincinnati

 
Where:
Grand Cypress Ballroom G

 

Brought to you by Sanofi-aventis U.S. and Regeneron Pharmaceuticals, Inc.

0
No votes yet



by Dr. Radut.